Silexion Therapeutics Corp
No enriched coverage for $SLXN in the last 7 days.
No SEC Form 4 filings for $SLXN in the last 30 days.
Shirvan Mitchell, CSO and CDO of Silexion Therapeutics (SLXN), reported selling 22,818 Ordinary Shares on March 26, 2026, at $1.36 per share. This transaction was a "sale-to-cover" to address tax liabilities from a fully vested restricted share unit grant received in February 2026. Following the sale, Mitchell directly holds 27,889 Ordinary Shares and an adjusted stock option for 478 Ordinary Shares.
Silexion Therapeutics (NASDAQ: SLXN) has received approval from the Israeli Ministry of Health to begin a Phase 2/3 clinical trial for SIL204, its drug candidate for locally advanced pancreatic cancer. The drug targets KRAS mutations, which are present in over 90% of pancreatic cancers, and has shown strong preclinical anti-tumor activity. Silexion plans to initiate human trials in Q2 2026 and expects to file for additional regulatory approvals in Germany and the EU by early 2027.
Grand Cayman, Cayman Islands, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Silexion Therapeutics Corp. ( "Silexion" or the "Company" ) , a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st ...
